MIAMI, Oct. 21, 2026 /PRNewswire/ — Resolve Therapeutics, LLC, a clinical-stage biotechnology company developing nuclease-Fc fusion proteins designed to degrade pathogenic extracellular nucleic acids, today announced two e-posters featuring preclinical data on its RNase-Fc fusion protein…